Liquidia Technologies
As of the edition of 20 October 2026, Liquidia Technologies runs 3 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Treprostinil | Ends 2028 (patent) | 3 |
A route B row is one company at one target.
Where its trials are
- Lungs and airways: 2 trials led
- Heart and blood vessels: 1 trials led
- Infections: 1 trials led